Prostate Cancer Principles and Practice

Prostate Cancer: Principles & Practice CONTENTS......Page 2
DEDICATION......Page 7
PREFACE......Page 9
1 - GROSS AND APPLIED ANATOMY OF THE PROSTATE......Page 11
2 - CELLULAR AND MOLECULAR BIOLOGY OF PROSTATIC DEVELOPMENT......Page 19
3 - NUCLEAR RECEPTORS IN NORMAL PROSTATIC GROWTH AND DISEASE......Page 26
4 - SOMATIC GENETICS OF PROSTATE CANCER: ONCOGENES AND TUMOR SUPPRESSORS......Page 39
5 - ANTISURVIVAL THERAPY FOR METASTATIC PROSTATE CANCER......Page 51
6 - EVOLUTION OF HORMONE-REFRACTORY PROSTATE CANCER......Page 58
7 - PROSTATE CANCER PREVENTION......Page 65
8 - NUTRITIONAL AND ENVIRONMENTAL EPIDEMIOLOGY OF PROSTATE CANCER......Page 71
9 - GENETIC EPIDEMIOLOGY OF PROSTATE CANCER......Page 82
10 - FAMILIAL PROSTATE CANCER......Page 89
11 - RACE AND RISK......Page 94
12 - CONSERVATIVE MANAGEMENT OF LOCALIZED PROSTATE CANCER......Page 102
13 - CLINICAL EPIDEMIOLOGY: INCIDENCE RATES, DATABASES, AGE, AND CO-MORBIDITY......Page 104
14 - SCREENING FOR PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN, DIGITAL RECTAL EXAMINATION, AND FREE, DENSITY, AND AGE-SPECIFIC DERIVATIVES......Page 113
15 - SERUM TUMOR MARKERS IN PROSTATE CANCER......Page 122
16 - SYSTEMATIC BIOPSY OF THE PROSTATE: APPLICATIONS FOR DETECTION, STAGING, AND RISK ASSESSMENT......Page 129
17 - PATHOLOGY......Page 134
18 - COMBINED-MODALITY STAGING IN PREDICTING PROSTATE-SPECIFIC ANTIGEN OUTCOME AFTER DEFINITIVE LOCAL THERAPY FOR MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER......Page 147
19 - IMAGING AND STAGING OF PROSTATE CANCER......Page 156
20 - MOLECULAR STAGING OF PROSTATE CANCER......Page 165
21 - SURGICAL THERAPY OF CLINICALLY LOCALIZED PROSTATE CANCER: RATIONALE, PATIENT SELECTION, AND OUTCOMES......Page 174
22 - EXTERNAL BEAM RADIATION THERAPY: CONVENTIONAL AND CONFORMAL......Page 180
23 - BRACHYTHERAPY AS MONOTHERAPY......Page 191
24 - NEW METHODS OF FOCAL ABLATION OF THE PROSTATE......Page 205
25 - QUALITY OF LIFE IN PROSTATE CANCER......Page 211
26A - MANAGEMENT CONSIDERATIONS OF URINARY INCONTINENCE AND ERECTILE DYSFUNCTION AFTER LOCAL THERAPY FOR PROSTATE CANCER......Page 218
26B - MANAGEMENT OF RADIATION INJURY TO THE BOWEL......Page 224
27 - MANAGEMENT CONSIDERATIONS FOR THE PATIENT WITH LOW-RISK DISEASE......Page 227
28 - COMBINED EXTERNAL BEAM RADIATION THERAPY OR BRACHYTHERAPY AND HORMONES......Page 233
29 - COMBINATION EXTERNAL BEAM RADIATION THERAPY AND BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER......Page 240
30 - PROTON BEAM THERAPY IN PROSTATE CANCER......Page 243
31 - NEOADJUVANT ANDROGEN DEPRIVATION BEFORE RADICAL PROSTATECTOMY FOR PROSTATE ADENOCARCINOMA......Page 247
32 - MANAGEMENT OF HIGH-RISK PROSTATE CANCER......Page 254
33 - ADJUVANT EXTERNAL BEAM RADIATION THERAPY POSTPROSTATECTOMY......Page 261
34 - ADJUVANT HORMONAL THERAPY FOR PROSTATE CANCER......Page 266
35 - DEFINING TREATMENT FAILURE AFTER LOCAL TREATMENT AND RESTAGING......Page 272
36 - LOCAL THERAPY FOR RECURRENT PROSTATE CANCER......Page 275
37 - SALVAGE RADIATION AFTER RADICAL PROSTATECTOMY......Page 282
38 - SYSTEMIC MANAGEMENT OF THE PATIENT WITH PROSTATE CANCER AND A RISING PROSTATE-SPECIFIC ANTIGEN AFTER DEFINITIVE TREATMENT......Page 288
39 - PROGNOSTIC FACTORS FOR RESPONSE AND SURVIVAL WITH HORMONE THERAPY......Page 292
40 - ANDROGEN ABLATION FOR PROSTATE CANCER: MECHANISMS AND MODALITIES......Page 297
41 - COMBINED ANDROGEN BLOCKADE FOR THE TREATMENT OF METASTATIC CANCER OF THE PROSTATE......Page 301
42 - ALTERNATIVE HORMONE APPROACHES: INTERMITTENT, PERIPHERAL, TRIPLE......Page 310
43 - SECOND LINE HORMONE THERAPY......Page 315
44 - PAIN AND SYMPTOM MANAGEMENT......Page 321
45 - MANAGEMENT OF BONE METASTASES: EXTERNAL BEAM RADIATION THERAPY, RADIOPHARMACEUTICALS, AND BISPHOSPHONATES......Page 337
46 - HEMATOLOGIC COMPLICATIONS OF PROSTATE CANCER......Page 342
47 - NEUROLOGIC COMPLICATIONS OF PROSTATE CANCER......Page 348
48 - ORTHOPEDIC CONSIDERATIONS: IMPLICATIONS AND MANAGEMENT OF METASTATIC PROSTATE CANCER......Page 357
49 - PSYCHOSOCIAL CONSIDERATIONS IN PROSTATE CANCER......Page 364
50 - CLINICAL TRIAL DESIGN FOR PROSTATE CANCER......Page 369
51 - CHEMOTHERAPY FOR ANDROGEN-INDEPENDENT PROSTATE CANC......Page 377
52 - NOVEL TUMOR-DIRECTED THERAPEUTIC STRATEGIES FOR HORMONE-REFRACTORY PROSTATE CANCER......Page 386
53 - TUMOR ENVIRONMENT AS THE TARGET: NOVEL THERAPEUTICS, INCLUDING ANTIANGIOGENESIS AND ANTIMETASTATICS......Page 393
54 - CANCER VACCINES AND GENETIC IMMUNOTHERAPY FOR PROSTATE CANCER......Page 400
55 - COMPLEMENTARY AND ALTERNATIVE MEDICINE......Page 407
Color Plate......Page 415